Skip to main
ACTU

ACTU Stock Forecast & Price Target

ACTU Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actuate Therapeutics is making steady progress with their elraglusib treatment for pediatric neuroblastoma, with an upcoming dose-confirmation cohort of 20 patients expected to define key metrics for the drug's use in combination with dinutuximab beta and chemotherapy. If approved, this could make Actuate eligible for a rare pediatric disease Priority Review Voucher, which could have a significant financial impact. Early preclinical data also supports continued development of intravenous elraglusib in multiple pediatric orphan oncology indications, and if successful, the drug could be eligible for a PRV upon approval.

Bears say

Actuate Therapeutics is facing a significant challenge in the high costs of product development, and a potential decrease in their cash flow due to the change in fair value of warrant liabilities. Despite upcoming preclinical data that may support combination use with RAS inhibitors, the company is still in early stages and facing uncertainty in their potential benefits from the combination therapy. Investors should approach this stock with caution, keeping in mind the company's current financial challenges and the lack of solid clinical data at this time.

ACTU has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actuate Therapeutics Inc (ACTU) Forecast

Analysts have given ACTU a Strong Buy based on their latest research and market trends.

According to 2 analysts, ACTU has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actuate Therapeutics Inc (ACTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.